system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
AMENDMENT 1 TO DEVELOPMENT AGREEMENT This is the First Amendment ("First Amendment") to the Development Agreement ("Development Agreement") entered into on April 15, 2010, by and between Cargill, Incorporated through its Bio Technology Development Center, having its principal place of business at 15407 McGinty Road West, Wayzata, Minnesota 55391 USA ("Cargill") and BioAmber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France ("BioAmber"). This First Amendment will be effective as of July 5, 2011, upon the signature of both Cargill and BioAmber. Cargill and Bioamber mutually agree as follows: The Parties, through their authorized representatives, hereby agree to the terms and conditions of this First Amendment. Cargill Confidential * Confidential treatment requested 1. Section 2.2 of the Development Agreement is hereby amended to allow Cargill at its sole discretion to apply [***] during the period of July 5, 2011, through September 30, 2011, to perform the Work Plan in addition to the [***] specified in the unamended Section 2.2. The terms for compensation and expenses for these additional FTEs will be as provided for the original FTEs in Section 2.2. 2. Other than as expressly modified by this First Amendment, all terms and conditions of the Development Agreement continue without modification. CARGILL, INCORPORATED Bio Technology Development Center BIOAMBER S.A.S. /s/ Jack Staboch /s/ Jim Millis Signature Signature VP BioTDC CTO Title Title 7/14/11 7/18/11 AMENDMENTS TO COMMERCIAL LICENSE AGREEMENT AND DEVELOPMENT AGREEMENT WHEREAS, Cargill, Incorporated ("Cargill") and BioAmber S.A.S. ("Bioamber") entered into a Development Agreement having an Effective Date of April 15 , 2010, as amended on July 5 , 2011 (the "Development Agreement"); WHEREAS, Cargill and Bioamber entered into a Commercial License Agreement having an Effective Date of April 15, 2010 (the "Commercial License"); WHEREAS, Bioamber now desires to amend the Development Agreement to allow Bioamber to fund a research project being conducted by the Biotechnology Research Institute ("BRI"), which involves the molecular re-engineering of a Methylotroph owned by BRI and the development of a lab scale fermentation design for using the re-engineered Methylotroph to make succinic acid or salts thereof from a methanol feedstock (the "BRI Project"). The BRI Project will be co-funded by funds available from the Canadian National Research Council; WHEREAS, Bioamber further desires to scale-up the production of succinic acid using a Corynebacteria biocatalyst (MCC-17) available from Mitsubishi Chemical Corporation ("MCC") and to possibly produce succinic acid or salts using MCC-17 as an alternative to the E. coli BioAmber has licensed from the DOE at: (1) Bioamber's existing demonstration-scale succinic acid production facility located at Pomacle, France; and (2) a succinic acid production facility located at Sarnia, Ontario Canada having a maximum production capacity of 35,000 metric tons of succinic acid per year (the "Sarnia Plant"). Together these scale-up projects will be referred to as the "Scale-up and Production Project"; WHEREAS, Cargill is willing to allow Bioamber to fund the BRI Project and to conduct the Scale-up and Production Project, subject to the following terms and conditions. Now therefore the Parties agree: Amendment To the Development Agreement A. Section 13.9 of the Development Agreement is amended to add the following at the end of the Section: "Notwithstanding the above, Bioamber may fund the BRI Project up until the Methylotroph (or re-engineered Methylotroph) demonstrates the ability to produce succinic acid (or salts thereof) from any feedstock at a concentration of [***] grams/liter succinic acid (or salts thereof). Within thirty (30) days of the Methylotroph (or re-engineered Methylotroph) demonstrating such production levels of succinic acid, Bioamber will cease any further funding and/or other support for the BRI Project. Further Bioamber will require that any unexpended funds received from Bioamber be utilized for a project other than the BRI Project. B. New Section 13.10 is added to the Development Agreement as set forth below: "13.10 Notwithstanding the provisions of section 13.9, Bioamber may conduct the Scale-up and Production Project, subject to Bioamber hereby agreeing to convert the demonstration-scale Pomacle France succinic acid production facility and the Sarnia Plant to solely utilize CB1 as the biocatalyst for the production of succinic acid (and/or salts thereof). This conversion will be carried out according to the provisions of Section 5.9 of the Commercial License, it being understood that all economic obligations of item (iv) above will be relative to the E. coli strain technology, not the Mitsubishi strain technology. In order to enable such conversion, Bioamber will put in place agreements with the owners/operators of the Sarnia Plant that will enable Bioamber to require such conversion of
"""

Extract the exact clause related to "Most Favored Nation" from the excerpt above.

assistant: Not found.